» Articles » PMID: 33775692

Coronavirus Disease 2019 Vaccine Response in Pregnant and Lactating Women: a Cohort Study

Abstract

Background: Pregnant and lactating women were excluded from initial coronavirus disease 2019 vaccine trials; thus, data to guide vaccine decision making are lacking.

Objective: This study aimed to evaluate the immunogenicity and reactogenicity of coronavirus disease 2019 messenger RNA vaccination in pregnant and lactating women compared with: (1) nonpregnant controls and (2) natural coronavirus disease 2019 infection in pregnancy.

Study Design: A total of 131 reproductive-age vaccine recipients (84 pregnant, 31 lactating, and 16 nonpregnant women) were enrolled in a prospective cohort study at 2 academic medical centers. Titers of severe acute respiratory syndrome coronavirus 2 spike and receptor-binding domain immunoglobulin G, immunoglobulin A, and immunoglobulin M were quantified in participant sera (n=131) and breastmilk (n=31) at baseline, at the second vaccine dose, at 2 to 6 weeks after the second vaccine, and at delivery by Luminex. Umbilical cord sera (n=10) titers were assessed at delivery. Titers were compared with those of pregnant women 4 to 12 weeks from the natural infection (n=37) by enzyme-linked immunosorbent assay. A pseudovirus neutralization assay was used to quantify neutralizing antibody titers for the subset of women who delivered during the study period. Postvaccination symptoms were assessed via questionnaire. Kruskal-Wallis tests and a mixed-effects model, with correction for multiple comparisons, were used to assess differences among groups.

Results: Vaccine-induced antibody titers were equivalent in pregnant and lactating compared with nonpregnant women (pregnant, median, 5.59; interquartile range, 4.68-5.89; lactating, median, 5.74; interquartile range, 5.06-6.22; nonpregnant, median, 5.62; interquartile range, 4.77-5.98, P=.24). All titers were significantly higher than those induced by severe acute respiratory syndrome coronavirus 2 infection during pregnancy (P<.0001). Vaccine-generated antibodies were present in all umbilical cord blood and breastmilk samples. Neutralizing antibody titers were lower in umbilical cord than maternal sera, although this finding did not achieve statistical significance (maternal sera, median, 104.7; interquartile range, 61.2-188.2; cord sera, median, 52.3; interquartile range, 11.7-69.6; P=.05). The second vaccine dose (boost dose) increased severe acute respiratory syndrome coronavirus 2-specific immunoglobulin G, but not immunoglobulin A, in maternal blood and breastmilk. No differences were noted in reactogenicity across the groups.

Conclusion: Coronavirus disease 2019 messenger RNA vaccines generated robust humoral immunity in pregnant and lactating women, with immunogenicity and reactogenicity similar to that observed in nonpregnant women. Vaccine-induced immune responses were statistically significantly greater than the response to natural infection. Immune transfer to neonates occurred via placenta and breastmilk.

Citing Articles

Efficacy and safety of SARS-CoV-2 vaccination in pregnancy to prevent COVID-19 in mothers and early infancy.

de Bruin O, Phijffer E, Ahmadizar F, Van der Maas N, Wildenbeest J, Sturkenboom M Cochrane Database Syst Rev. 2025; 2:CD015785.

PMID: 40008623 PMC: 11863297. DOI: 10.1002/14651858.CD015785.


Maternal and Placental Antibody Responses in SARS-CoV-2 Vaccination and Natural Infection During Pregnancy.

Sturrock S, Cavell B, Alexander F, Apostolakis K, Barro C, Daniel O Pediatr Infect Dis J. 2025; 44(2S):S32-S37.

PMID: 39951071 PMC: 7617455. DOI: 10.1097/INF.0000000000004704.


Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.

Didembourg M, David C, Morimont L, Cransquint E, Favresse J, Douxfils J Heliyon. 2025; 11(1):e41249.

PMID: 39811280 PMC: 11729664. DOI: 10.1016/j.heliyon.2024.e41249.


Infant Passive Protection Against Coronavirus Through Exclusive Breastfeeding: A Cross-Sectional Study.

Amaral Y, Nardi A, Marano D, Carioca da Costa A, Moreira M Nutrients. 2025; 17(1.

PMID: 39796564 PMC: 11723047. DOI: 10.3390/nu17010130.


Assessment of Placental Antioxidant Defense Markers in Vaccinated and Unvaccinated COVID-19 Third-Trimester Pregnancies.

Rolfo A, Cosma S, Nuzzo A, Moretti L, Tancredi A, Canosa S Life (Basel). 2025; 14(12.

PMID: 39768279 PMC: 11677986. DOI: 10.3390/life14121571.


References
1.
Mazur N, Horsley N, Englund J, Nederend M, Magaret A, Kumar A . Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness. J Infect Dis. 2018; 219(1):59-67. PMC: 6284547. DOI: 10.1093/infdis/jiy477. View

2.
Dreier J, Nybo Andersen A, Berg-Beckhoff G . Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. Pediatrics. 2014; 133(3):e674-88. DOI: 10.1542/peds.2013-3205. View

3.
Zipursky J, Greenberg R, Maxwell C, Bogler T . Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making. CMAJ. 2021; 193(9):E312-E314. PMC: 8034306. DOI: 10.1503/cmaj.202833. View

4.
Ellington S, Strid P, Tong V, Woodworth K, Galang R, Zambrano L . Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(25):769-775. PMC: 7316319. DOI: 10.15585/mmwr.mm6925a1. View

5.
Riley L, Jamieson D . Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts. Ann Intern Med. 2021; 174(5):701-702. PMC: 7875205. DOI: 10.7326/M21-0173. View